| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/21/2004 | US20040209886 nitrogen compounds such as 3-Cyano-4-[4-(cyano-phenyl-methyl)-phenylamino]-5-methyl-pyrrolo[1,2-b]pyridazine-6-carboxylic acid ethyl ester and optionally with carriers used as antiproliferative agents; enzyme inhibitors |
| 10/21/2004 | US20040209885 Combination therapy for the treatment of heart failure |
| 10/21/2004 | US20040209883 Nitrogen-containing heterocyclic compounds and their use as raf inhibitors |
| 10/21/2004 | US20040209882 e.g., 2-{[4-(Cyclohexylmethyl-amino)-6-(3-fluoro-4-methoxy-phenylamino)-[1,35]triazin-2-ylamino]-methyl}-cyclopentanone; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme |
| 10/21/2004 | US20040209881 e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme |
| 10/21/2004 | US20040209880 e.g., 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3 ,5]triazine-2,4-diamine; inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells and inhibit smooth muscle proliferation. |
| 10/21/2004 | US20040209879 Piperidinyl derivates as modulators of chemokine receptor activity |
| 10/21/2004 | US20040209878 7-amino-pyrrazolo[1,5-a]pyrimidine derivatives, useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis |
| 10/21/2004 | US20040209874 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE) |
| 10/21/2004 | US20040209873 Arylcycloalkyl derivatives having branched side chains, processes for their preparation and their use as pharmaceuticals |
| 10/21/2004 | US20040209872 Calcium channel blockers comprising two benzhydril moieties |
| 10/21/2004 | US20040209871 Fused bicyclic nitrogen-containing heterocycles |
| 10/21/2004 | US20040209870 contain 5-HT ligands used to treat central nervous system disorders |
| 10/21/2004 | US20040209869 Method of treating lower urinary tract disorders |
| 10/21/2004 | US20040209868 Substituted indoles |
| 10/21/2004 | US20040209867 for treatment of disorders (sleeping, feeding) relating to or affected by the 5-HT6 receptor; serotonin receptor antagonists |
| 10/21/2004 | US20040209866 1,8 Naphthyridine derivatives and their use to treat diabetes and related disorders |
| 10/21/2004 | US20040209863 5-chloro-N-(5-chloropyridin-2-yl)-2-[(4-{(Z)-(dimethylamino)[(methylsulfonyl)imino]methyl}benzoyl)amino]benzamide; treating thromboembolic disorders, optionally with other active agents |
| 10/21/2004 | US20040209861 Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease |
| 10/21/2004 | US20040209860 compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation |
| 10/21/2004 | US20040209859 Fused cycloalkyl amides and acids and their therapeutic applications |
| 10/21/2004 | US20040209858 for example, N-(2-amino-2-oxoethyl)bicyclo[2.2.1]heptane-2-carboxamide or 2,3-dimethylcyclohexanecarboxamide; use treating epilepsy, bipolar disorder, migraine, neuropathic and inflammatory pain |
| 10/21/2004 | US20040209856 Oral pharmaceutical products containing 17beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation |
| 10/21/2004 | US20040209855 use of estradiol metabolites such as 2-methoxyestradiol, 4-methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol; few side effects |
| 10/21/2004 | US20040209853 Orally active 7.alpha.-alkyl androgens |
| 10/21/2004 | US20040209852 Formulations and methods for treating rhinosinusitis |
| 10/21/2004 | US20040209850 synergistic mixture of an analgesic ( opioid, NSAID, COX-2 inhibitor, acetaminophen, or tramadol) and a beta adrenergic agonist; faster response and longer duration; reduced gastrointestinal side effects |
| 10/21/2004 | US20040209849 treating a patient diagnosed with a non-anticholinergic state of delirium using an acetylcholine esterase inhibitor such as rivastigmine, galantamine, tacrine and donepezil, wherein said delirium occurs without anticholinergically acting substances being administered beforehand |
| 10/21/2004 | US20040209848 Administering to a patient (11 alpha , 15 alpha , 13E)-9-oxo-11,15-dihydroxy- 16-(3-methoxymethylphenyl)-17, 18, 19, 20-tetranor-5-thiaprost-13-enoic acid methyl ester, or cyclodextrin clathrate for treating osteoporosis |
| 10/21/2004 | US20040209846 Heterocyclic analgesic compounds and methods of use thereof |
| 10/21/2004 | US20040209845 Novel styrylacrylonitrile compounds which are useful in treating a variety of cell proliferative disorders such as cancer and specifically acute lymphoblastic leukemia; (E,E)-2-(benzylamido)-3-styrylacrylonitrile for example |
| 10/21/2004 | US20040209844 Compositions and methods for preventing infection |
| 10/21/2004 | US20040209843 addtion of a cyclodextrin compound increases the water solubility; storage stable solution; immediately treating symptoms of acute phases of myocardial or a cerebral infarction |
| 10/21/2004 | US20040209841 Association compound of trehalose or maltitol with metal ion compound |
| 10/21/2004 | US20040209834 mouse double minute (MDM); determining the mdm2-dependent growth activity of a cell by introducing vectors for expressing a p53 polypeptide or fragment into the cell, and measuring the growth of the cell |
| 10/21/2004 | US20040209832 RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| 10/21/2004 | US20040209828 Solvent-free anthracycline derivatives |
| 10/21/2004 | US20040209827 Macrolide antibiotics; prodrug |
| 10/21/2004 | US20040209826 Diphosphate salt of a "4" - substituted-9-deoxo-9 A - AZA - homoerythromycin derivatives and its pharmaceutical composition |
| 10/21/2004 | US20040209825 Inhibition by 3-deoxyflavonoids of T-lymphocyte activation and therapies related thereto |
| 10/21/2004 | US20040209824 administering a sulfamate compound (topiramate) to mammals |
| 10/21/2004 | US20040209823 Bicyclic carbohydrate compounds useful in the treatment of infections caused by Flaviviridae sp., such as hepatitis C and bovine viral diarrhea viruses |
| 10/21/2004 | US20040209822 Novel compounds |
| 10/21/2004 | US20040209821 Administering to treat acute coronary syndrome selected from myocardial infarction, congestive heart failure, and cardiac arrhythmias |
| 10/21/2004 | US20040209818 Immunomodulating polymers |
| 10/21/2004 | US20040209817 Methods and compositions for the treatment of peripheral artery disease |
| 10/21/2004 | US20040209805 such as fibrosis via activin antagonist (fullistatin); kits; gene therapy; treating inflammatory bowel disease and crohn's disease |
| 10/21/2004 | US20040209799 comprises inhibitors (cytokines) of janus kinases (JAK)/signal transducers and activators of transcription (STAT) other than debromohymenialdisine and hymensialdisine; gene expression inhibition; bioassay, immunoassay, drug screening; for treatment of degenerative joint diseases such as osteoarthritis |
| 10/21/2004 | US20040209366 Methods for attaching proteins to lipidic microparticles with high efficiency |
| 10/21/2004 | US20040209342 Comprises nucleotide sequences coding hydrolase for use in identifying modulators for treatment of diabetes and inflammatory diseases |
| 10/21/2004 | US20040209308 Methods of assaying receptor activity and constructs useful in such methods |
| 10/21/2004 | US20040209296 Using transcription factor inhibitors and human leukocyte antigen antibodies to prevent and treatcell proliferfative disorders; genetic vaccines and antitumor agents |
| 10/21/2004 | US20040209271 Dna providing system |
| 10/21/2004 | US20040209264 Comprises nucleotide sequences coding daugther of legless protein for use in identifying modulator for tissue regeneration and repair and the treatment of blood disorders |
| 10/21/2004 | US20040208944 Compositions and methods against inflammatory processes |
| 10/21/2004 | US20040208941 Compositions for removal of toxins |
| 10/21/2004 | US20040208939 Novel dietary compositions to reduce inflammation |
| 10/21/2004 | US20040208938 for needles comprising time release microparticles containing risperidones, glycolic acid-lactic acid copolymer binders, and high viscosity aqueous fluids (containing sodium carboxymethyl cellulose as modifier) |
| 10/21/2004 | US20040208935 Small particle liposome aerosols for delivery of anti-cancer drugs |
| 10/21/2004 | US20040208934 Dispersions or complexes of calcium phosphate in polymers such as polyethylene glycol or dextran sulfate; solid matrix due to hydration; contains active agent; matrix polymer and/or complexing agent slows release of active agent from solid matrix |
| 10/21/2004 | US20040208932 moisture stable pharmaceutical preparation in form of solid oral dose comprising active core of granulated pharmaceutically active ingredient and moisture barrier coating enveloping individual granules of active core |
| 10/21/2004 | US20040208930 produced by coating core particles with layer containing water-soluble drug and forming film layer containing water-insoluble polymer and plasticizer on particles and forming water-soluble filler layer between water-soluble drug-containing layer and film layer |
| 10/21/2004 | US20040208927 Process for preparing non-hygroscopic sodium valproate composition |
| 10/21/2004 | US20040208925 alendronate particles coated with polymer insoluble at pH 6-7.5, and alginic acid or sodium alginate or admixtures there of, where alendronate dissolves in 900 ml 0.1 N HCl at the rate of not less than 85% within 30 minutes at pH 1-4; decreases esophageal and gastric side effects of alendronate |
| 10/21/2004 | US20040208924 active pharmaceutical ingredient is for example [(2S)-Sulfanyl-5-[(N,N-dimethylamino)acetyl]aminopentanoyl-L-leucyl-L-tert-leucine N-methylamide; bonding strength, stability |
| 10/21/2004 | US20040208923 administering a therapeutically effective amount of a pharmacologic agent that enhances learning or conditioning within 24 hours prior to conducting session of psychotherapy |
| 10/21/2004 | US20040208918 administering constituent which effects a local increase in temperature and/or an increase in blood flow of the skin in addition to the transdermally applied active substance |
| 10/21/2004 | US20040208910 Sustained release device and method for ocular delivery of adrenergic agents |
| 10/21/2004 | US20040208908 chlorhexidine, triclosan, minocycline, bismuth nitrate, silver carbonate or silver sulfadiazine; polyvinylchloride (PVC), silicon, polytetrafluoroethylene (PTFE), silk or cotton fiber; wound dressings, sutures, catheters |
| 10/21/2004 | US20040208902 comprises a zeolite composition, skin beneficial compositions requiring a controlled-release topical delivery, and a cosmetically or pharmaceutically acceptable delivery system, or a carrier base composition; antiaging, anti-wrinkle, antioxidants, skin whitening, acne treatment, rosacea, sunscreen |
| 10/21/2004 | US20040208893 Seaweed extract composition for treatment of diabetes and diabetic complications |
| 10/21/2004 | US20040208891 Prevention and treatment of bronchial asthma |
| 10/21/2004 | US20040208889 Pharmaceutical use for secreted bacterial effector proteins |
| 10/21/2004 | US20040208884 Administering construct in conjugated or unconjugated form and in combination with immunogenic carrier to induce antibodies; anticarcinogenic agents |
| 10/21/2004 | US20040208882 Ltb4 as vaccine adjuvant |
| 10/21/2004 | US20040208878 Treatment of acute lung injury, fibrosis and metastasis with antagonists of alphabetav6 |
| 10/21/2004 | US20040208875 Method for treating amyloidosis |
| 10/21/2004 | US20040208870 Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| 10/21/2004 | US20040208869 Preventing or treating an autoimmune disease, bone or metabolic disorder associated with aberrant expression of integrin alpha v beta 3 by administering an antibody or antibody fragment that immunospecifically binds to integrin alpha v beta 3; antiinflammatory agents |
| 10/21/2004 | US20040208864 Methods of improving health-related quality of life in individuals with systemic lupus erythematosus |
| 10/21/2004 | US20040208859 Bile acid absorbent/adsorbent |
| 10/21/2004 | US20040208855 Use of PDT to inhibit intimal hyperplasia |
| 10/21/2004 | US20040208845 Delivering structurally reinforcing agents into a ventricle to increase compliance; prevention of remodeling and thinning of infarct zone by crosslinking collagen; pro-fibroblastic, antiischemic and angiogenic agents |
| 10/21/2004 | US20040208844 Products and drug delivery vehicles |
| 10/21/2004 | US20040208840 Topically applying a mixture of peroxide and a transitional metal to increase the efficacy of the peroxide in acne and skin disorder treatment |
| 10/21/2004 | US20040208836 Packaged retinoid for topical administration; indicia indicates application to skin about eight hours prior to exposure to ultraviolet radiation to effect said diminution; sunscreen agents; aging resistance |
| 10/21/2004 | US20040208834 Oral-use polymer and oral-use composition |
| 10/21/2004 | US20040208831 Nasal pharmaceutical formulations and methods of using the same |
| 10/21/2004 | US20040208830 Fluticasone powders has specific particle size distribution; increase bioavailability, prolonged therapeutic effect of the drug substance; aqueous suspension for inhalation; drug delivery method and device; rhinitis treatment |
| 10/21/2004 | US20040208829 Methods and compositions for treating erectile dysfunction |
| 10/21/2004 | US20040208822 technetium labelled complexes; for the treatment or diagnosis of pathologies caused by attack on human cartilage, arthritis |
| 10/21/2004 | DE10316280A1 Pharmazeutisches Schaumaerosol für Dexpanthenol A pharmaceutical aerosol foam for panthenol |
| 10/21/2004 | DE10313272A1 Using hexadecylphosphocholine for treatment of actinic keratosis, by topical application as aqueous solution |
| 10/21/2004 | DE102004016947A1 Feste pharmazeutische Zusammensetzung A solid pharmaceutical composition |
| 10/21/2004 | DE102004010921A1 Feste Oraldosierungsform von Metformin und Glyburid sowie ein Verfahren zu Ihrer Herstellung Oral solid dosage form of metformin and glyburide and a process for their preparation |
| 10/21/2004 | CA2707750A1 Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol |
| 10/21/2004 | CA2528001A1 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 10/21/2004 | CA2526869A1 Oral pharmaceutical preparation comprising a proton pump antagonist and a basic exipient |
| 10/21/2004 | CA2523186A1 Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby |
| 10/21/2004 | CA2522231A1 Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |